Introduction to CKS1BP5 (G100526793)

Target Name: CKS1BP5

NCBI ID: G100526793

CKS1BP5

Other Name(s): CDC28 protein kinase regulatory subunit 1B pseudogene 5

Introduction to CKS1BP5

CKS1BP5, also known as CDC28 protein kinase regulatory subunit 1B pseudogene 5, is a fascinating drug target and potential biomarker that has gained attention in recent years. In this article, we will explore the various aspects of CKS1BP5, its role in cancer, and its potential as a therapeutic target or diagnostic biomarker.

1. The Role of CKS1BP5 in Cancer:

CKS1BP5 is a pseudogene that is primarily associated with cancer development and progression. Studies have shown that CKS1BP5 is overexpressed in various types of cancer, including breast, lung, prostate, and colorectal cancer. Its overexpression has been associated with poor prognosis and increased tumor aggressiveness.

2. CKS1BP5 as a Therapeutic Target:

Due to its involvement in cancer, CKS1BP5 has emerged as a potential therapeutic target. Several studies have explored the use of CKS1BP5 inhibitors to suppress its activity and inhibit cancer cell growth. Preclinical studies have shown promising results, with CKS1BP5 inhibitors inhibiting tumor growth and enhancing the effectiveness of existing chemotherapeutic agents.

3. Challenges in Targeting CKS1BP5:

While CKS1BP5 holds great promise as a therapeutic target, there are several challenges associated with its targeting. One major challenge is the lack of selective inhibitors. Developing selective inhibitors that exclusively target CKS1BP5 without affecting other important cellular processes is crucial to avoid potential side effects.

4. CKS1BP5 as a Diagnostic Biomarker:

In addition to its therapeutic potential, CKS1BP5 also shows promise as a diagnostic biomarker. Studies have demonstrated that CKS1BP5 is upregulated in cancer tissues compared to normal tissues, making it a potential biomarker for early cancer detection. Furthermore, its expression levels have been correlated with cancer stage and progression, highlighting its potential as a prognostic indicator.

5. CKS1BP5's Mechanism of Action:

To understand how CKS1BP5 functions as a therapeutic target or diagnostic biomarker, it's essential to delve into its mechanism of action. CKS1BP5 is involved in the regulation of the cell cycle and cell division. It interacts with cyclin-dependent kinases (CDKs) to inhibit their activity, leading to cell cycle arrest and suppression of cell growth. Dysregulation of this interaction can result in uncontrolled cell proliferation, a hallmark of cancer.

6. Future Directions and Potential Applications:

Given the promising preclinical results and the growing understanding of CKS1BP5's role in cancer, further research is warranted to explore its full potential as a therapeutic target or biomarker. Future studies can focus on developing selective CKS1BP5 inhibitors, investigating its role in different cancer types, and examining its association with treatment response and resistance.

Conclusion:

CKS1BP5 holds immense potential as a drug target and biomarker in cancer. Its overexpression in various cancer types, coupled with its involvement in cell cycle regulation, makes it an attractive candidate for targeted therapy. Additionally, its upregulation in cancer tissues and correlation with cancer stage and progression suggest its utility as a diagnostic biomarker. While challenges in targeting CKS1BP5 persist, continued research efforts may yield novel therapeutic strategies and diagnostic tools to combat cancer more effectively.

Protein Name: CDC28 Protein Kinase Regulatory Subunit 1B Pseudogene 5

The "CKS1BP5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CKS1BP5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets